Treatment Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer (mcrpc) and Cardiovascular Disorders or Diabetes: the Prostate Cancer Registry.

e16537 Background: The Prostate Cancer Registry is a prospective study of >3000 men with mCRPC in routine care. These patients (pts) have a high level of comorbidities which are often underrepresented in RCTs. Methods: Data were collected from pts with mCRPC irrespective of treatment (tx). Outcomes in pts with comorbidities were assessed. Results: At study entry, 16.6% of pts had a cardiac disorder, 9.7% hypertension only, 17.7% diabetes. Characteristics, first txs and outcomes are shown in the table below. Conclusions: In this real-life setting, AAP, ENZ, or DOC tx was feasible in pts with cardiac disorders, hypertension or diabetes; proportions treated with each drug were similar to the overall mCRPC population. Regardless of tx PFS was shorter than TTP, which may reflect the impact of pts’ comorbidities in real life. Pts with cardiac disorders had poorer outcomes vs the overall population. Clinical trial information: NCT02236637. [Table: see text]